T2 Biosystems
T2 Biosystems Receives Nasdaq Delisting Notice
In October, the company regained compliance with the Nasdaq minimum bid price requirement after undergoing a reverse stock split.
In Brief This Week: Thermo Fisher, Myriad Genetics, T2 Biosystems, DermTech, More
News items for the week of Oct. 30, 2023
T2 Biosystems Gets FDA 510(k) Clearance for Biothreat Panel
The clearance allows the firm to immediately begin marketing an assay that simultaneously detects six biothreat pathogens directly from blood.
Earnings Roundup: T2 Biosystems, Personalis, Standard BioTools, Biodesix, MyHealthChecked
These genomics and diagnostics firms posted their quarterly financial results this week.
In Brief This Week: DermTech, Waters, ERS Genomics, Transomic, Karius, T2 Biosystems, More
News items for the week of July 31, 2023
Feb 15, 2023
T2 Biosystems Prices $12M Public Offering
Oct 14, 2022
Canaccord Downgrades T2 Biosystems to Hold
Aug 30, 2022